Recent News

• 04.25.2025 - Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
• 04.25.2025 - Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
• 04.02.2025 - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.02.2025 - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.25.2025 - Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
• 03.25.2025 - Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
• 03.18.2025 - Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
• 03.18.2025 - Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 04.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.18.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.18.2025 - EX-99.1 EX-99.1
• 03.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.18.2025 - 8-K Current report
• 03.05.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities